{"Symbol": "APRE", "AssetType": "Common Stock", "Name": "Aprea Therapeutics Inc", "Description": "Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.", "CIK": "1781983", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "3805 OLD EASTON ROAD, DOYLESTOWN, PA, UNITED STATES, 18902", "OfficialSite": "https://aprea.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "4262000", "EBITDA": "-13795074", "PERatio": "None", "PEGRatio": "None", "BookValue": "1.825", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-2.12", "RevenuePerShareTTM": "0.08", "ProfitMargin": "0", "OperatingMarginTTM": "-1686.9", "ReturnOnAssetsTTM": "-0.419", "ReturnOnEquityTTM": "-0.747", "RevenueTTM": "488240", "GrossProfitTTM": "-7905043", "DilutedEPSTTM": "-2.12", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.995", "AnalystTargetPrice": "5.33", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "2", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "8.73", "PriceToBookRatio": "0.386", "EVToRevenue": "-", "EVToEBITDA": "0.346", "Beta": "1.61", "52WeekHigh": "3.715", "52WeekLow": "0.548", "50DayMovingAverage": "0.852", "200DayMovingAverage": "1.403", "SharesOutstanding": "6993800", "SharesFloat": "4713600", "PercentInsiders": "19.624", "PercentInstitutions": "22.627", "DividendDate": "None", "ExDividendDate": "None"}